International Journal of Medical Science and Pharmaceutical Research

Glioblastoma, IDH-wildtype, CNS WHO grade 4, is an infiltrative and immunologically complex adult-type diffuse glioma with poor prognosis despite maximal safe resection, radiotherapy, temozolomide, and selected use of tumor-treating fields. The current histomolecular definition of glioblastoma, together with its antigenic heterogeneity, myeloid-rich tumor microenvironment, blood-brain/tumor barrier, treatment-induced lymphopenia, and corticosteroid-associated immunosuppression, creates major challenges for immunotherapy. Dendritic-cell vaccines and cytokine-induced killer cell-based therapy provide complementary biological solutions. Dendritic-cell vaccines can process broad tumor-antigen repertoires and prime adaptive antitumor immunity, whereas CIK cells provide ex vivo-expanded cytotoxic effector function with T-cell and natural killer-like properties. This review synthesizes developments over the last decade in glioblastoma-directed DC vaccination, CIK-cell therapy, and DC-CIK strategies, while situating them within the broader landscape of surgery, radiochemotherapy, tumor-treating fields, immune checkpoint blockade, CAR-T cells, oncolytic virotherapy, anti-angiogenic therapy, and recurrent-disease management. Current evidence supports the safety and biological plausibility of DC and CIK-based immunotherapy, with encouraging survival signals from DCVax-L and randomized CIK-cell studies. However, definitive implementation requires molecularly homogeneous cohorts, standardized GMP-compliant manufacturing, validated potency assays, steroid-adjusted immune monitoring, biomarker-guided patient selection, and rational combination designs. DC and DC-CIK platforms should therefore be viewed not as isolated alternatives but as immune-amplifying components of multimodal neuro-oncology.

Glioblastoma, dendritic-cell vaccine, cytokine-induced killer cells, DC-CIK, cancer vaccine, immunotherapy, tumor microenvironment, neuro-oncology, cell therapy

1. Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23(8):1231-1251. doi:10.1093/neuonc/noab106.
2. Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2021;18(3):170-186. doi:10.1038/s41571-020-00447-z.
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996. doi:10.1056/NEJMoa043330.
4. Stupp R, Taillibert S, Kanner A, Read W, Steinberg DM, Lhermitte B, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma. JAMA. 2017;318(23):2306-2316. doi:10.1001/jama.2017.18718.
5. Kotecha R, Odia Y, Khosla AA, Ahluwalia MS. Key clinical principles in the management of glioblastoma. JCO Oncol Pract. 2023;19(3):180-189. doi:10.1200/OP.22.00476.
6. Regev O, Merkin V, Blumenthal DT. Tumor-treating fields for the treatment of glioblastoma: a review of the evidence. Onco Targets Ther. 2021;14:4051-4060. doi:10.2147/OTT.S295940.
7. Khagi S, Chan D, Rivera AL, Ahluwalia MS. Recent advances in tumor treating fields therapy for glioblastoma. Cancers (Basel). 2024;16:review article. doi:10.3390/cancers.
8. Fisher JP, Adamson DC. Current FDA-approved therapies for high-grade malignant gliomas. Biomedicines. 2021;9(3):324. doi:10.3390/biomedicines9030324.
9. Antonelli M, Poliani PL. Adult type diffuse gliomas in the new 2021 WHO Classification. Pathologica. 2022;114(6):397-409. doi:10.32074/1591-951X-816.
10. Fernandes RT, et al. The 2021 World Health Organization classification of gliomas. Radiol Bras. 2023;56:282-291.
11. Guo X, Pan Y, Xiong M, et al. Histological and molecular glioblastoma, IDH-wildtype: a real-world landscape. Front Oncol. 2023;13:1200815. doi:10.3389/fonc.2023.1200815.
12. Mair MJ, Geurts M, van den Bent MJ, Berghoff AS. A basic review on systemic treatment options in WHO grade 4 gliomas. Cancer Treat Rev. 2021;92:102124. doi:10.1016/j.ctrv.2020.102124.
13. Jackson CM, Choi J, Lim M. Mechanisms of immunotherapy resistance: lessons from glioblastoma. Nat Immunol. 2019;20(9):1100-1109. doi:10.1038/s41590-019-0433-y.
14. Lim M, Weller M, Idbaih A, Steinbach J, Finocchiaro G, Raval RR, et al. Phase 3 trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter. Neuro Oncol. 2022;24(11):1935-1949. doi:10.1093/neuonc/noac116.
15. Reardon DA, Brandes AA, Omuro A, Mulholland P, Lim M, Wick A, et al. Effect of nivolumab versus bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial. JAMA Oncol. 2020;6(7):1003-1010. doi:10.1001/jamaoncol.2020.1024.
16. Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med. 2019;25(3):477-486. doi:10.1038/s41591-018-0337-7.
17. Sampson JH, Omuro AMP, Preusser M, et al. A randomized phase III trial of rindopepimut plus temozolomide in patients with newly diagnosed EGFRvIII-expressing glioblastoma. Neuro Oncol. 2018;20(5):605-614. doi:10.1093/neuonc/nox175.
18. Wen PY, Reardon DA, Armstrong TS, Phuphanich S, Aiken RD, Landolfi JC, et al. A randomized double-blind placebo-controlled phase II trial of dendritic cell vaccine ICT-107 in newly diagnosed glioblastoma. Clin Cancer Res. 2019;25(19):5799-5807. doi:10.1158/1078-0432.CCR-19-0261.
19. Liau LM, Ashkan K, Brem S, Campian JL, Trusheim JE, Iwamoto FM, et al. Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma. JAMA Oncol. 2023;9(1):112-121. doi:10.1001/jamaoncol.2022.5370.
20. Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, et al. First results on survival from a large phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J Transl Med. 2018;16:142. doi:10.1186/s12967-018-1507-6.
21. Wong CE, Chang Y, Chen PW, Huang YT, Chang YC, Chiang CH, et al. Dendritic cell vaccine for glioblastoma: an updated meta-analysis and trial sequential analysis. J Neurooncol. 2024;170:review. doi:10.1007/s11060-024-04798-w.
22. Ridolfi L, Petrini M, Granato AM, et al. First step results from a phase II study of a dendritic cell vaccine in high-grade gliomas. Front Immunol. 2024;15:1404861. doi:10.3389/fimmu.2024.1404861.
23. Subtirelu RC, Borloveanu R, Shaikh N, et al. Advancements in dendritic cell vaccination for glioblastoma. Front Neurol. 2023;14:1271822. doi:10.3389/fneur.2023.1271822.
24. Prins RM, Soto H, Konkankit V, Odesa SK, Eskin A, Yong WH, et al. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res. 2011;17(6):1603-1615. doi:10.1158/1078-0432.CCR-10-2563.
25. Kong DS, Nam DH, Kang SH, Lee JW, Chang JH, Kim JH, et al. Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma. Oncotarget. 2017;8(4):7003-7013. doi:10.18632/oncotarget.12273.
26. Han MH, Lee YJ, Kim TM, Nam DH. Efficacy of cytokine-induced killer cell immunotherapy for patients with pathologically pure glioblastoma. Cancers. 2022;14(8):1960. doi:10.3390/cancers14081960.
27. Jiang W, He Y, He W, Wu G, Zhou X, Sheng Q, et al. Combined immunotherapy with dendritic cells and cytokine-induced killer cells for solid tumors: a systematic review and meta-analysis. J Transl Med. 2024;22:1159. doi:10.1186/s12967-024-05940-y.
28. Lueck AS, Pu J, Melhem A, Schneider M, Sharma A, Schmidt-Wolf IGH, Maciaczyk J. Preclinical evaluation of DC-CIK cells as potentially effective immunotherapy model for the treatment of glioblastoma. Sci Rep. 2025;15:734. doi:10.1038/s41598-024-84284-5.
29. Introna M, Correnti F. Innovative clinical perspectives for CIK cells in cancer patients. Int J Mol Sci. 2018;19(2):358. doi:10.3390/ijms19020358.
30. Schmeel FC, Schmeel LC, Gast SM, Schmidt-Wolf IGH. Adoptive immunotherapy strategies with cytokine-induced killer cells in the treatment of hematological malignancies. Int J Mol Sci. 2014;15(8):14632-14648. doi:10.3390/ijms150814632.
31. Palmerini P, Dalla Pieta A, Sommaggio R, Ventura A, Astori G, Chieregato K, et al. A serum-free protocol for the ex vivo expansion of cytokine-induced killer cells using gas-permeable static culture flasks. Cytotherapy. 2020;22(9):511-518. doi:10.1016/j.jcyt.2020.05.003.
32. Jiang Y, Wang X, Zhang Y, et al. Current status of cytokine-induced killer cells and combination strategies in cancer immunotherapy. Front Immunol. 2025;16:1476644. doi:10.3389/fimmu.2025.1476644.
33. Liu H, Zhang Y, Wang J, et al. Dendritic cell-cytokine-induced killer cells co-loaded with multiple antigens and poly(I:C) improve antitumor activity. Biomolecules. 2025;15(10):1356. doi:10.3390/biom15101356.
34. Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med. 2016;375(26):2561-2569. doi:10.1056/NEJMoa1610497.
35. Choi BD, Yu X, Castano AP, Darr H, Henderson DB, Bouffard AA, et al. CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. Nat Biotechnol. 2019;37(9):1049-1058. doi:10.1038/s41587-019-0192-1.
36. Bagley SJ, Desai AS, Linette GP, June CH, O'Rourke DM. CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges. Neuro Oncol. 2018;20(11):1429-1438. doi:10.1093/neuonc/noy032.
37. Desjardins A, Gromeier M, Herndon JE 2nd, Beaubier N, Bolognesi DP, Friedman AH, et al. Recurrent glioblastoma treated with recombinant poliovirus. N Engl J Med. 2018;379(2):150-161. doi:10.1056/NEJMoa1716435.
38. Chiocca EA, Nassiri F, Wang J, Peruzzi P, Zadeh G. Viral and other therapies for recurrent glioblastoma: is a 24-month durable response possible? Neuro Oncol. 2019;21(1):14-25. doi:10.1093/neuonc/noy170.
39. Martikainen M, Essand M. Virus-based immunotherapy of glioblastoma. Cancers (Basel). 2019;11(2):186. doi:10.3390/cancers11020186.
40. Filley AC, Henriquez M, Dey M. Recurrent glioma clinical trial, CheckMate-143: the game is not over yet. Oncotarget. 2017;8(53):91779-91794. doi:10.18632/oncotarget.21586.
41. Quail DF, Joyce JA. The microenvironmental landscape of brain tumors. Cancer Cell. 2017;31(3):326-341. doi:10.1016/j.ccell.2017.02.009.
42. Neftel C, Laffy J, Filbin MG, Hara T, Shore ME, Rahme GJ, et al. An integrative model of cellular states, plasticity, and genetics for glioblastoma. Cell. 2019;178(4):835-849.e21. doi:10.1016/j.cell.2019.06.024.
43. Hara T, Chanoch-Myers R, Mathewson ND, Myskiw C, Atta L, Bussema L, et al. Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma. Cancer Cell. 2021;39(6):779-792.e11. doi:10.1016/j.ccell.2021.05.002.
44. Friebel E, Kapolou K, Unger S, Nunez NG, Utz S, Rushing EJ, et al. Single-cell mapping of human brain cancer reveals tumor-specific instruction of tissue-invading leukocytes. Cell. 2020;181(7):1626-1642.e20. doi:10.1016/j.cell.2020.04.055.
45. Pombo Antunes AR, Scheyltjens I, Lodi F, Messiaen J, Antoranz A, Duerinck J, et al. Single-cell profiling of myeloid cells in glioblastoma across species and disease stage. Nat Neurosci. 2021;24(4):595-610. doi:10.1038/s41593-020-00789-y.
46. Ghimire P, Kinnersley B, Karami G, Arumugam P, Houlston R, Ashkan K, et al. Radiogenomic biomarkers for immunotherapy in glioblastoma: a systematic review. medRxiv. 2024. doi:10.1101/2024.05.13.24307337.
47. Minniti G, Niyazi M, Alongi F, Navarria P, Belka C. Current status and recent advances in reirradiation of glioblastoma. Radiat Oncol. 2021;16:36. doi:10.1186/s13014-021-01767-9.
48. Lombardi G, De Salvo GL, Brandes AA, Eoli M, Ruda R, Faedi M, et al. Regorafenib compared with lomustine in patients with relapsed glioblastoma: the REGOMA trial. Lancet Oncol. 2019;20(1):110-119. doi:10.1016/S1470-2045(18)30675-2.
49. Wen PY, Packer RJ. The 2021 WHO classification of tumors of the central nervous system: clinical implications. Neuro Oncol. 2021;23(8):1215-1217. doi:10.1093/neuonc/noab120.
50. Narsinh KH, Tu-Chan AP, Rutledge WC, et al. Strategies to improve drug delivery across the blood-brain barrier for glioblastoma. Curr Neurol Neurosci Rep. 2024;24:123-139.
51. Sharma A, Schmidt-Wolf IGH. Advancing CIK cell immunotherapy: highlights from the International Society for CIK Cells. Cancer Immunol Immunother. 2025;74:article. doi:10.1007/s00262-025-04216-8.